



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>4</sup> : A61K 37/18, 31/195		A1	(11) International Publication Number: WO 88/ 01872
			(43) International Publication Date: 24 March 1988 (24.03.88)
(21) International Application Number: PCT/US87/02279 (22) International Filing Date: 8 September 1987 (08.09.87) (31) Priority Application Number: 905,934 (32) Priority Date: 10 September 1986 (10.09.86) (33) Priority Country: US (71) Applicant: DUDRICK MEDICAL RESEARCH FUND I, LTD. [US/US]; 3600 Allied Bank Plaza, Houston, TX 77002 (US). (72) Inventor: DUDRICK, Stanley, J. ; 6448 Fannin - 11th Floor, Houston, TX 77030 (US). (74) Agent: CHRYSTAL, John, J.; Ladas & Parry, 104 S. Michigan Avenue, Chicago, IL 60603 (US).		(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BG, BJ (OAPI patent), BR, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CM (OAPI patent), DE, DE (European patent), DK, FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent).  Published <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: METHOD AND SUBSTRATE COMPOSITION FOR TREATING ATHEROSCLEROSIS			
(57) Abstract			
<p>The method involves parenterally administering the substrate composition as an aqueous solution to substantially lower plasma cholesterol and substantially reverse arterial plaque deposition and degenerative changes associated with atherosclerosis. The substrate compositions include mixtures of biologically active levorotatory amino acids as the antiatherosclerotic agent.</p>			

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

-1-

METHOD AND SUBSTRATE COMPOSITION FOR TREATING  
ATHEROSCLEROSIS

The present invention relates generally to compositions and methods for treating atherosclerosis; more particularly, it relates to methods and substrate compositions for treating atherosclerosis whereby the many  
5 and varied problems associated with the disease can be arrested, substantially alleviated or even to a certain extent cured. Still more particularly, the present invention utilizes mixtures of biologically active levorotatory (L-form) amino acids to accomplish these  
10 results.

In the United States and Western Europe, cardiovascular disease and its associated maladies, dysfunctions and complications are a principal cause of disability and the chief cause of death. One specific  
15 entity significantly contributing to this pathophysiologic process is atherosclerosis, which has been generally recognized as the leading health care problem both with respect to mortality and health care costs. During each  
20 of the past five years, more than 550,000 deaths have occurred annually in the United States alone as a result of coronary artery disease. Additionally, more than 680,000 hospitalizations for myocardial infarction, the major complication of atherosclerosis, occur annually, and  
25 the number is steadily increasing. In recent years, more people in the United States have died as a result of atherosclerosis than of cancer, trauma and infectious diseases combined.

In 1983, the direct health care costs for the management of patients with coronary heart disease in the

SUBSTITUTE SHEET

United States exceeded \$8 billion. During the same period the total economic cost to this nation as a result of coronary heart disease as a manifestation of atherosclerosis along was in excess of \$60 billion and for 1987 is estimated to reach \$96 billion. These costs do not even reflect the expense required for the management or treatment of the many and varied non-cardiac, atherosclerosis induced conditions.

Atherosclerosis is a disease characterized by the deposition of fatty substances, primarily cholesterol, and subsequent fibrosis in the inner layer (intima) of an artery, resulting in plaque deposition on the surface of, and degenerative changes in, an arterial wall. The ubiquitous arterial fatty plaque is the earliest lesion of atherosclerosis, often found even in children, and is a grossly flat, lipid-rich atheroma consisting of both macrophages (white blood cells) and some smooth muscle fibers. The fibrous plaque representative of the various forms of advanced atherosclerosis has increased intimal smooth muscle cells surrounded by a connective tissue matrix and containing variable amounts of intracellular and extracellular lipid. At the luminal surface of the artery, this plaque or lesion is usually covered by a dense fibrous cap of smooth muscle or connective tissue. Beneath the fibrous cap, the lesions are highly cellular consisting of macrophages, other leukocytes and smooth muscle cells. Deep in this cell-rich region may be areas of cholesterol crystals, necrotic debris and calcification.

If the disease is allowed to progress, it can cause narrowing and obstruction of the lumen of the artery resulting in diminished or occluded blood flow and, consequently, ischemia or infarction of the predominantly affected organ or anatomical part such as the brain, heart, intestine or extremities. The result can be significant loss of function, loss of cellular substance, emergency medical and/or surgical procedures, and

**SUBSTITUTE SHEET**

significant disability or death. Alternatively, the arterial wall can be severely weakened by the infiltration of the muscular layer with the lipid (cholesterol), inflammatory white blood cells, connective tissue and calcium, resulting in soft and/or brittle areas which can become segmentally dilated (aneurysmal) and rupture or crack leading to organ, limb or even life-threatening hemorrhage.

While the basic definitive cause or causes of atherosclerosis are not fully known or understood, it has been hypothesized that this disorder is related to the plasma cholesterol and lipid levels based on empiric clinical observations of many investigators and medical practitioners. Consequently, one of the currently favored regimens for treating atherosclerosis consists of medication, dietary management, behavior modification and exercise aimed at controlling and reducing the plasma cholesterol levels.

Common medications used to lower plasma cholesterol levels include Atromide-S<sup>®</sup> (clofibrate), Cholesterol<sup>®</sup> (dextrothyroxine sodium), Colestid<sup>®</sup> (colestipol hydrochloride), Lipid<sup>®</sup> (gemfibrozil), Lorelco<sup>®</sup> (probucol), Nicolar<sup>®</sup> (niacin/nicotinic acid) and Questran<sup>®</sup> (cholestyramine resin). These drugs, and the treatments in general, however, are directed only at the cause and not the result of atherosclerosis and have not been shown to be effective in reversing the plaque deposition and degenerative changes in the arterial walls. The pharmacologic agents also have many other shortcomings such as, for example, adverse side effects (hypertension, cardiac arrhythmias, gastrointestinal disturbances, headache, hypersensitivity, etc.), contraindications (heart, liver or kidney disease, pregnancy, etc.), requirement for lifelong conscientious administration, difficulty in maintaining consistent patient compliance, variable reliability and high cost.

Once the disease has progressed to the stage of significant persistent symptoms and compromised function, the next treatment step has conventionally been artery bypass grafting to repair and/or replace the damaged artery. While coronary artery bypass has become one of the more common major cardiovascular surgical procedures in the United States, surgery clearly is not the solution to the pathologic process since it has no arresting or reversing effect on the progress of the disease and only temporarily overcomes the most critically affected artery or arteries by bypassing them, if possible. Moreover, there is a significant risk of morbidity and mortality associated with surgery which many patients are reluctant to accept. Indeed, the disease may continue to progress even as the operation is being performed, and the autogenous veins or arteries used to bypass the disease impaired arteries undergo atherosclerosis changes postoperatively generally at a faster rate than the original affected arteries. Furthermore, the conclusion reached by the Coronary-Artery Surgery Study (CASS) sponsored by the national Heart, Lung and Blood Institute (NHLBI) is that there is no overall statistical benefit in the survival rate or the rate of development of myocardial infarction between the surgically and medically treated groups of patients.

As an alternative to coronary bypass surgery, it has been suggested that certain medications and procedures may be used to treat the results of atherosclerosis and not just the cause. These treatments include chelation with ethylene diamine tetraacetic acid (EDTA) and percutaneous transluminal coronary angioplasty (PTCA). EDTA treatments, however, are still experimental, unproven and potentially as harmful as they are beneficial. PTCA treatments are invasive, of limited application and success and occasionally manifest lethal complications. Highly experimental intra-arterial laser beam plaque

vaporization has limited application and requires an open operative approach to affected vessels.

It has now been surprisingly discovered that parenterally administered solutions comprising certain mixtures of biologically active amino acids are effective in both markedly reducing plasma cholesterol levels and arresting and reversing arterial plaque deposition and degenerative vascular changes associated with atherosclerosis.

Certain amino acid solutions have been parenterally administered intravenously during the past three or four decades for a variety of medical reasons. Total Parenteral Nutrition (TPN), or intravenous hyperalimentation, is now a widely accepted technique for management of nutritional and metabolic problems in patients whose absorption and assimilation of adequate optimal nutritional substrates cannot or should not be achieved via the alimentary tract. Indeed, use of this technique, pioneered by the present inventor, has been successful in supporting normal growth and development in infants and in one child for more than fifteen years since birth.

Currently, a number of standard TPN solutions are commercially available in the United States, including those sold under the trade name Travosol<sup>®</sup> (Travenol Laboratories), Freamine<sup>®</sup> (McGaw Laboratories), Aminosyn<sup>®</sup> (Abbott Laboratories) and Novamine (Cutter Medical, division of Miles Laboratories). These standard intravenous feeding solutions are designed to be nutritionally balanced, that is, they are formulated to provide all of the caloric, protein (amino acid), vitamin, mineral, water and trace element requirements of the average patient. The components of these solutions are also available in modular form, allowing the physician and pharmacist to formulate special solutions tailored to the specific needs of patients during the course of their management. Essential fatty acids and additional calories in the form of a lipid can also be administered separately

**SUBSTITUTE SHEET**

intravenously as fortified emulsions of soybean or safflower oil in order to meet specific nutritional requirements. In patients with renal failure, hepatic failure or severe stress, special intravenous formulations of amino acids are also commercially available for infusion as an adjunct to the management of these conditions. For example, U.S. Patent No. 3,832,465 describes an amino acid solution for nutritional use and U.S. Patent No. 3,950,529 describes administration of amino acids to patients having liver disease.

No suggestion has been made, however, that parenterally administered biologically active amino acid solutions might be used to treat atherosclerosis, particularly with respect to the reversal of the detrimental complications associated with the disease.

It is, therefore, an object of the present invention to provide amino acid compositions and methods for treating atherosclerosis whereby not only the plasma cholesterol levels (contributing cause) are lowered, but also the plaque deposition and degenerative arterial changes (results) and secondary complications associated with the disease can be substantially arrested, reversed or even to a certain extent cured.

It is a further object of the present invention to provide amino acid compositions and methods for treating atherosclerosis which do not produce the many side effects of conventional drug treatments and can effectively decrease or even eliminate the need for major surgery or other interventional procedures in most atherosclerosis patients.

#### SUMMARY OF THE INVENTION

In accordance with the present invention, there are provided methods and substrate compositions for use in treating atherosclerosis, a disease characterized by the deposition of fatty substances in, and fibrosis of, the inner layer of an artery resulting in plaque deposition on



and degenerative changes in an arterial wall. The methods and compositions of the present invention are particularly advantageous in that they work to both significantly lower plasma cholesterol levels and substantially arrest, reverse and, to a certain extent, even cure the arterial plaque deposition and degenerative vascular wall changes associated with atherosclerosis.

The compositions of the present invention comprise, in their overall concept, at least in part an active antiatherosclerotic agent which in turn comprises a mixture of biologically active (L-form) amino acids. This mixture more preferably comprises at least arginine and the branched chain amino acids, isoleucine, leucine and valine, with arginine preferably being present within the mixture in the greatest weight percentage based upon the total weight of the amino acids in the mixture. Even more preferably the mixture also includes lysine, methionine, phenylalanine, threonine, tryptophan and histidine. Most preferably, the mixture also includes alanine, proline, serine, tyrosine, glycine, glutamic acid, aspartic acid and cysteine.

The compositions of the present invention may also comprise, in addition to the amino acid mixture, other nutrients or additives such as vitamins, minerals, electrolytes, carbohydrates, antibiotics, anticoagulants and the like as required by the specific needs of a patient.

The compositions of the present invention are preferably administered parenterally in the form of an aqueous solution through a central venous catheter due to the hypertonic nature of the preferred aqueous solutions. The daily ration of the aqueous solution is further preferably administered continuously and constantly intravenously by an intravenous infusion pump.

The primary advantages of this invention over other methods of managing patients with atherosclerosis include

the following: plasma cholesterol levels can be lowered more promptly and to a greater extent than heretofore achieved with any previous therapeutic modality; the degree and extent of atherosclerosis plaque regression is greater than has ever been demonstrated previously; the duration of therapy required to reverse the atherosclerosis plaque is relatively short compared with the duration of time over which the plaque had originally developed; all of the solution ingredients are biologically active nutrient substrates with negligible toxicity or adverse side effects when administered in the proposed dosage ranges; the cost/effectiveness and cost/benefit ratios compare favorably with pharmacologic and surgical approaches to treating atherosclerosis; the therapy can be initiated and carried out entirely on an outpatient basis; and the method addresses and attacks the basic pathophysiology of atherosclerosis primarily and biochemically rather than pharmacologically or by dealing only with complications of atherosclerosis surgically.

These and other features and advantages of the present invention will be more readily understood by those skilled in the art from a reading of the following detailed description and examples with reference to the accompanying drawing.

#### BRIEF DESCRIPTION OF THE DRAWING

Fig. 1 is a graphical representation of the daily plasma total cholesterol levels of the human patient whose treatment is described in Example 2 demonstrating the responses elicited by changes in the formulation of the infusate.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention provides methods and substrate compositions for treating atherosclerosis which, as previously mentioned is a disease characterized by the deposition of fatty substances, primarily cholesterol, as plaque and subsequent fibrosis in the inner layer (intima)

of an artery. As also previously mentioned, atherosclerosis is believed to be related at least in part to plasma cholesterol and lipid levels. The compositions and methods of the present invention are particularly effective in both lowering plasma cholesterol levels (contributing cause) and also in reversing the arterial plaque deposition and degenerative changes (result) to substantially arrest, alleviate and, to a certain extent, even cure the many and varied problems, conditions and secondary complications associated with the disease.

The compositions of the present invention, in their overall concept, are comprised of biological substrates including at least, in part, an active antiatherosclerosis agent. Antiatherosclerosis, as used herein, refers to both the lowering of plasma cholesterol levels and the arrest and reversal of arterial plaque deposition and degenerative arterial wall changes. The active antiatherosclerosis agent, in the preferred embodiment, is a mixture of biologically active amino acids, preferably L-form amino acids.

Biologically active amino acids are generally classified as either essential or nonessential. Essential amino acids are those that cannot be synthesized within the body and must be ingested in adequate amounts in the diet. Non-essential amino acids, conversely, are those that can be synthesized biochemically within the body from other substrate sources. The amino acids most commonly classified as essential include isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine. The amino acids most commonly classified as non-essential include alanine, arginine, histidine, proline, serine, tyrosine, glycine, glutamic acid, aspartic acid and cysteine. Arginine and histidine have been classified as semiessential in that they appear to be essential for infants and to some extent in the presence of renal failure.

These biologically active amino acids also exist in dextrorotatory or D-form and levorotatory or L-form. The L-form is considerably more biologically active than the D-form and is, therefore, preferred for use as the antiatherosclerosis agent.

The substrate compositions of the present invention are placed in an aqueous solution which, in turn, is parenterally administered to a patient as the treatment. When so administered the compositions of the present invention result in substantial lowering of plasma cholesterol levels and substantial reversal of the arterial plaque deposition on, and degenerative changes in, the arterial system.

The antiatherosclerosis agent preferably is a mixture of at least arginine, isoleucine, leucine and valine, preferably with arginine being present in the greatest weight percentage based upon the total weight of the biologically active amino acids in the mixture. These amino acids preferably comprise at least about 25% by weight of the amino acids present, but can, for brief infusion periods, be the sole active ingredients. The mixture may also include various of the other amino acids. Most preferably, all of the above-listed amino acids are present within the mixture to provide administration of all the amino acids along with other ingredients in a nutritionally balanced solution. All of these ingredients are a part of TPN solutions but, surprisingly, increased levels of the branched chain amino acids and arginine, often coupled with the reduction of amounts of histidine in the amino acid mixture, results in prompt (usually about one week) dramatic (usually 40% to 60%) reduction in plasma cholesterol. Also of note is the reduction of the simplest amino acids, particularly alanine and glycine, most particularly glycine, from TPN

solutions.

The amino acids are included in the preferred amino acid mixtures in the approximate weight percentage ranges based upon the total weight of the amino acids in the mixture as set forth in Table I below.

TABLE I

	Amino Acid		Amino Acid	
	Approximate Weight		Approximate Weight %	
	Isoleucine	3 - 10	Alanine	2 - 20
10	Leucine	3 - 10	Histidine	1 - 4
	Lysine	2.5 - 7.5	Proline	0 - 10
	Methionine	2.5 - 7.5	Serine	0 - 8
	Phenylalanine	3 - 10	Tyrosine	0 - 1
	Threonine	1 - 4	Glycine	0 - 10
15	Tryptophan	1 - 3	Glutamic Acid	0 - 6
	Valine	3 - 10	Aspartic Acid	0 - 6
	Arginine	7 - 20	Cysteine	0 - 1

Note the non-essential amino acids listed above as being optional ingredients in the broad sense of this invention may contribute less to atherosclerosis recovery than the other species. The same may hold true for alanine and the non-branched chain essential amino acids. These amino acids, however, are important from a nutritional point of view when patient treatment extends over a period of months. As such, these amino acids may be added in greater or lesser amounts than listed above without materially affecting or altering the characteristics and advantages of the solution and, therefore, without departing from practicing the present invention. Thus, a more preferred amino acid mixture comprised of the foregoing amino acids present in the following approximate weight percentages based upon the total weight of the amino acids in the mixture as set

forth in Table II below.

TABLE II

Amino Acid		Approximate Weight %	Amino Acid		Approximate Weight %
5	Isoleucine	4 - 10	Alanine	7	-16
	Leucine	5 - 10	Histidine	1.5 - 3.5	
	Lysine	4.5 - 6.5	Proline	4.5 - 8.5	
	Methionine	3.5 - 5.5	Serine	2.5 - 6.5	
	Phenylalanine	4.5 - 7.5	Tyrosine	0 - 1	
10	Threonine	2 - 3.5	Glycine	3 - 8	
	Tryptophan	1 - 2.5	Glutamic Acid	3.5 - 5.5	
	Valine	4 - 9	Aspartic Acid	2 - 4	
	Arginine	9 - 18	Cysteine	0 - 1	

The amino acid mixtures are preferably accomplished by mixing the crystalline forms of the amino acids, usually the acetate, chloride and hydrochloride salt. A balance of the ions used in the salts is required to avoid upsetting the acid/base balance within the body of the patient; usually about 80% acetate and 20% chloride and hydrochloride. Usually the pH of the solution of the invention will range from about 5.0 to about 7.8 but preferably will be adjusted to the pH of blood, approximately 7.39, by the addition of a suitable non-toxic organic compound. The crystalline form of amino acid is preferred due to its high purity and the precise, reproducible formations which can be produced from such. Further, solutions made from the crystalline form can be directly assimilated into the body without preliminary biological action within the body. The mixture of amino acids can also be formulated using commercially available parenteral nutrition (TPN) solutions and adding amino acids, preferably in crystalline form, to achieve solutions of the invention. Preferred TPN solutions include those sold under the trademark Travasol®.

Additionally, the compositions of the present invention may include other essential nutrients such as vitamins, minerals, electrolytes, carbohydrates, antibiotics, anticoagulants and the like as required for nutritional, antibacterial and anticlotting purposes and other biological supports as will be recognized by one skilled in the art. As in substantially all biological applications, however, the most preferred compositions will be patient specific, that is, the actual amino acid mixture may be varied based upon a variety of factors which normally determine medication compositions and dosages such as, for example, the reaction of the specific patient to the composition; the tolerance of the specific patient to the individual and combined components; the stage and extent of the disease; the predominant organ(s) or system(s) adversely affected by the disease; the primary biologic functions adversely affected by the disease and/or its complications; the existence, nature and extent of concomitant malnutrition, the comprehensive clinical symptom complex of the patient; the stage of the recovery and from surgical or other procedural attempts at alleviating signs and symptoms of the disease and/or its complications; the age, sex and general condition of the patient; the presence of other concomitant disorders (diabetes mellitus, familial hyperlipidemia, etc.); and other factors as will be appreciated by those skilled in the art.

These factors are all related to the ability of a patient to utilize or tolerate the amino acid mixture and other components of the compositions of the present invention. In other words, each patient may require some adjustment of specific ingredients at various stages during the treatment as a result of one or more of the above-listed factors. For example, a diabetic may not be able to tolerate as high a caloric content in the form of a sugar as a person without diabetes. As another example,

it is known that the amino acid requirements of a person with renal or liver failure are different from those of a person without these conditions. As still another example, a person suffering from malnutrition may require greater amounts of, and different, amino acids and other nutrients than a well-nourished person. One skilled in the art will be able to recognize these special needs and be able to adjust the compositions of the present invention accordingly.

Other adjustments to the amino acid mixture may be determined from blood and urine amino acid profiles. These profiles are indicative of how the body is utilizing a specific amino acid, and any deficiency or excess can be determined from such profiles and compensated for by altering the amino acid mixture. One skilled in the art will be able to make the desired adjustments accordingly once such an amino acid profile has been determined. The amino acid profile is adjusted in response to blood and urine analysis to determine the utilization of the amino acids by the body of the patient. It has been found that the antiatherosclerotic effect is largely determined by the amount of branched chain amino acids and arginine in the treatment. The significance of arginine as an important amino acid has heretofore been overlooked but, surprisingly, in the practice of this invention has emerged as an important contributor.

The compositions of the present invention are preferably administered parenterally in the form of an aqueous intravenous solution. The aqueous solution, therefore, comprises the composition as an additive solute in solution with an aqueous solvent base. The aqueous solvent base preferably comprises a sterile, ion-free water base to which may be added a variety of components depending upon the composition of the amino acid mixture and the specific needs of the individual patient. For example, if the composition does not have sufficient



caloric value and the patient requires additional caloric intake, the aqueous solvent base may be a dextrose-water, fructose-water or invert sugar-water solution (equal parts of dextrose and fructose) including variable concentrations of the carbohydrate substrates chosen to meet the caloric needs of the patient. The solutions are compounded using established aseptic, antiseptic and pharmacochemical techniques well known to those skilled in the art to insure the complete solubility of the ingredients while maintaining the stability, sterility, safety and preferred formulation for the individual patients.

It is preferable that the active antiatherosclerotic agent, that is, the amino acid mixture, be present in solution in an effective amount which, when the solution is parenterally administered using hyperalimentation techniques well known to those skilled in the art, results in substantial lowering of plasma cholesterol and substantial reversal of arterial plaque deposition and degenerative arterial wall changes after a relatively short period of administration, usually within two to six months while at the same time providing the body of the patient nutrition necessary to sustain life. The amino acid mixture is present within the aqueous solution in concentrations ranging from as low as about 4 grams total weight of amino acids per 100 ml of solution (a 4% by weight solution) up to the solubility limits of the specific amino acid mixture within the particular aqueous solvent (sometimes as high as a 20% by weight in solution). Preferably, the amino acid mixture is present within the solution in concentrations ranging from about 7.5 to about 12 grams total weight of amino acids per 100 ml of solution (a 7.5% to 12% by weight solution). These concentrations will result in a hypertonic solution (800 to 1100 milliosmols per liter), that is, a solution having a higher osmotic pressure than blood (290 to 310

milliosmols per liter), the significance of which is discussed below. For the specific effective composition described above, it is preferable that the amino acid mixture be present in solution in a concentration of from  
5 about 9 to about 11, more preferably from about 10 to about 11, grams of amino acids per 100 ml of solution.

The aqueous solutions of the present invention are administered parenterally since the oral route has a number of disadvantages. When administered orally, the  
10 amino acids are subjected to the modifying digestive actions of the stomach, intestinal tract, pancreas and liver; the endogenous cycle exerts a buffering effect on the components of the formulation; the pattern of solutions to be administered is difficult to determine in  
15 order that the resultant blood levels of the active antiatherosclerosis agents be achieved identical to those induced by direct intravenous infusion; and methods of controlling precise levels of intake are difficult to establish and maintain. By parenteral administration, a  
20 direct assault can be launched against target tissues, and in some instances it is even possible to isolate a part of the body and perfuse it with the amino acid solution for hours, days or weeks without drastically altering the patient's normal nutritional patterns. Furthermore,  
25 parenteral administration permits constant, controlled administration, thus ensuring a continuity of effect without the nadirs or zeniths which inevitably occur following oral or enteral administration and subsequent absorption and assimilation.

30 Since the preferred aqueous solution will be hypertonic (about 800 to about 1100 milliosmols per liter), these solutions should be administered intravenously through a large diameter blood vessel having high blood flow for substantially instant dilution, most  
35 preferably through a central venous catheter inserted percutaneously into the superior vena cava by any one of

several acceptable methods known to those skilled in the art. A particularly preferred method of catheter insertion is described in the article by O'Donnell, Calgue and Dudrick entitled "Percutaneous Insertion of a Cuffed Catheter with a Long Subcutaneous Tunnel for Intravenous Hyperalimentation," published in Southern Medical Journal, Volume 76, No. 11 (1983), pages 1344-48, which is hereby incorporated by reference herein for all purposes as if fully set forth.

After catheterization has been achieved, continuous infusion of the aqueous antiatherosclerosis solution can begin. The total daily solution ration for the individual patient is preferably administered in an amount sufficient to provide the patient with between about 0.25 and about 3.5 grams amino acids, more preferably between about 1 and about 2 grams amino acids, per kilogram of body weight per 24-hour day. This solution ration is also preferably administered continuously and constantly intravenously by commercially available intravenous infusion pumps to maintain a consistent amino acid level within the body.

During the course of extended infusion therapy, generally from about two months to about eight months, the patient preferably will not ingest any additional nutrient substrates which can affect the amino acid balance or metabolism within the body. The patient will be allowed to drink non-nutrient fluids and to ingest whatever oral medications which may be required during the course of the therapy. In selected patients, it will be feasible to infuse the solution on an ambulatory or outpatient basis using portable lightweight pumps and custom made support apparatus for the solution, infusion tubing and pump. In even more highly selected patients, it may be preferable to infuse the entire daily ration of solution in 12-16 hours of the 24 hour day, allowing the patients to disconnect themselves from the pump and infusion apparatus for eight to twelve hours in order to increase their

freedom and activities during the non-infusion periods. Whenever the patient is disconnected from the infusion tubing, it will be necessary to instill 1-2 ml of solution containing about 100 units heparin per ml into the central catheter and cap it with a sterile cap (for example, Luer-lock<sup>®</sup>) to prevent occlusion of the catheter with a blood clot.

During the first few weeks of infusion of the antiatherosclerosis solution, the patient should be monitored biochemically, hematologically and metabolically every 1-3 days via blood and urine specimens. Serum and/or urine amino acid profiles may be obtained from the specimens as desired and the amino acid mixtures adjusted accordingly. When initial stability of these indices has been achieved in response to the aqueous solution infusion and any indicated changes made in the initial composition of the solution, the intervals of monitoring can be extended to every 1-2 weeks.

Other indices to be monitored include the following: serum cholesterol, cholesterol esters, apolipoprotein A<sub>1</sub>, apolipoprotein B<sub>100</sub>, high density lipoprotein (HDL) cholesterol, triglycerides, sodium, potassium, chloride, bicarbonate, creatinine, calcium, inorganic phosphorus, glucose, urea nitrogen, uric acid, total protein, albumin, bilirubin, alkaline phosphatase, LDH, SGOT, SGPT, GGT, CPK, magnesium, zinc copper, blood prothrombin time, partial thromboplastin time, leukocyte count, erythrocyte count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, differential leukocyte count and platelet count. These standard tests are used individually, in various combinations and collectively to ensure the safety and efficacy of the treatment, to maintain homeostasis and to further assist the clinician in adjusting the solution specifically for the individual patient.

The foregoing detailed discussion of this invention will be further exemplified by the following specific examples offered by way of illustration and not limitation of the above described invention.

5

EXAMPLE 1

Attempts to implicate cholesterol as one of the primary etiologic agents in atherogenesis have been impaired somewhat by the inability to reduce and maintain lowered serum cholesterol levels by dietary and/or  
10 chemotherapeutic means alone. In a series of preliminary investigations, an animal model of atherosclerosis was developed over a period of several years by modifying the diet of New Zealand albino rabbits. Using several hundred male and female rabbits in a variety of studies while  
15 sequentially and logically modifying the diets, a consistent and reliable animal model was developed for inducing atherogenesis in these rabbits which simulated the distribution, various stages and severity, gross morphology and histologic characteristics, primary  
20 pathophysiology, secondary complications and clinical manifestations of atherosclerosis similar to that which has been observed and documented in human beings.

Rabbits, as herbivores, normally ingest only small quantities of dietary cholesterol. The inability of the  
25 rabbit livers of those rabbits to clear large quantities of dietary cholesterol biochemically resulted in a rapid increase in plasma cholesterol concentration, which in turn resulted in a reproducible degree, pattern and extent of atherosclerosis to advanced stages over a defined  
30 period of time proportional to the elevation of plasma cholesterol concentration and duration of the hypercholesterolemia.

As a result of the preliminary studies, an atherogenic diet was formulated and used to induce  
35 atherosclerosis in several hundred additional rabbits which were used as subjects in subsequent studies. In a

typical study, 40 New Zealand albino adult male and female rabbits were all fed a basic laboratory rabbit diet (Teklad<sup>®</sup> T.D. 82135) consisting of high fiber Purina<sup>®</sup> Labchow 5326 fortified with 8% peanut oil by weight as the carrier for 2% crystalline cholesterol by weight. Within ten days to two weeks after initiation of this oral dietary regimen, the plasma total cholesterol levels rose to about 1000 mg/dL and were maintained between 1000 and 2000 mg/dL for the remainder of the six week atherogenic period.

At six weeks, ten rabbits were killed and autopsied in order to delineate and document the gross and microscopic severity, stage and extent of the disease in these animals as a baseline. The remaining 30 rabbits in the initial groups were assigned randomly to one of three study groups. Group I consisted of ten animals which were continued on the atherogenic dietary regimen for an additional six weeks. Group II consisted of ten animals which received standard laboratory rabbit (Teklad<sup>®</sup> T.D. 82135) diet without the peanut oil and crystalline cholesterol for six weeks. Group III consisted of ten animals which were infused continuously with an antiatherosclerosis solution for six weeks via a central venous catheter positioned in the superior vena cava in a manner known to those skilled in the art. The amino acid composition of the antiatherosclerotic solution containing 4.25% (by weight) amino acids and 25% (by weight) dextrose is listed below in Table III (Column A). The solution was administered to provide 1.5 grams of amino acids and 35 calories per kilogram body weight daily with vitamins, minerals and trace elements being added to achieve a balanced nutrient mixture.

TABLE III

	Amino Acid	Weight %		Amino Acid	Weight %	
		A	B		A	B
	Isoleucine	4.7	6.3	Alanine	20	15.8
5	Leucine	5.9	7.4	Histidine	4.1	3.2
	Lysine	5.9	6.3	Proline	9.4	8.4
	Methionine	5.9	5.3	Serine	7.0	6.3
	Phenylalanine	5.9	6.3	Tyrosine	0.5	0.4
	Threonine	3.5	3.2	Glycine	9.4	6.3
10	Tryptophan	2.4	2.1	Glutamic Acid	-	3.2
	Valine	4.7	6.3	Aspartic Acid	-	2.1
	Arginine	10.0	10.5	Cysteine	0.7	0.6

At the end of the second six week study period, all 30 rabbits were killed and autopsied to determine and delineate the severity, stage and distribution of atherosclerosis. In the Group I rabbits, complicated atherosclerosis lesions were induced which reproducibly and consistently involved approximately 85% to 95% of the aorta from its origin at the heart to the bifurcation of the common iliac arteries, with the pattern of superficial plaque and arterial wall distribution characteristic of atherosclerosis lesions observed in human beings. Several of the rabbits in Group I showed evidence of having sustained human like myocardial infarctions, cerebral infarctions, intestinal ischemia and infarction, and ischemia and infarction in the hind extremities.

The rabbits in Group II which were fed the standard laboratory rabbit diet for the six weeks did not exhibit any regression of the atherosclerosis plaque when compared with the initial group of ten rabbits killed after six weeks on the atherogenic diet. Instead, there was slight progression of the atherosclerosis in Group II during this second six week period.

In the Group III rabbits receiving the special

atherosclerosis intravenous formulation, however, dramatic regressions occurred in the atherosclerosis plaques. In fact, the aorta was about 90% free of any evidence of atherosclerosis. In response to plasma and urine amino acid concentrations measured at weekly intervals in the Group III rabbits, the daily intravenous amino acid ration was increased from 1.5 to 1.7 grams per kilogram body weight, and glutamic acid and aspartic acid were added to the formulation. The final amino acid composition for Group III rabbits is shown in Column B, Table III. Note that the greatest increases occurred in the branched chain amino acids in the composition while arginine was increased slightly. These experiments were repeated until a total of 200 rabbits were studied in each of the three groups with results consistent with those above.

This investigation demonstrates consistent atherosclerosis plaque regression as a result of intravenous amino acid management alone. These studies formed the basis and justification for progressing to subsequent investigations in human patients.

Chronologically, studies at this point were begun in human patients using the antiatherosclerosis solution of the same composition which was infused into the last set of forty rabbits.

25

EXAMPLE 2

A forty year old man with severe generalized atherosclerosis secondary to familial Type II hyperlipidemia previously treated at a lipid research clinic with a combination of low cholesterol/fat, low calorie (1400 calories) diet and cholestyramine was considered for treatment using the solutions of this invention. Even after five months of this prior treatment, the patient's plasma cholesterol level could only be reduced from a baseline of 496 mg/dL to 409 mg/dL (top normal plasma cholesterol level is 260 mg/dL) and the patient did not experience any relief of his symptoms



detailed below. Within two weeks of voluntary cessation of this prior regimen, the plasma cholesterol returned to levels between 490 and 536 mg/dL.

The patient has recovered from a myocardial  
5 infarction one year earlier, but continued to have angina pectoris, could walk only one block without severe leg cramps and claudication, and had frequent fainting spells and numbness in his extremities related to poor blood flow in his major arteries. Four of the eight distal extremity  
10 pulses commonly palpated in the arms and legs were absent, and the remainder were diminished in strength by about 50%. Coronary angiography demonstrated complete occlusion of his right main coronary artery with diffuse narrowing and impaired blood flow in his left interior descending  
15 and circumflex coronary arteriest secondary to atherosclerosis. There is no evidence of significant collateral myocardial circulation, and because of the generalized diffuse extent of his disease, he was not a potential candidate for coronary artery bypass surgery.

20 His prognosis for life was less than two years. His plasma cholesterol concentration was 540 mg/dL, he was barely ambulatory and fainting spells had increased in frequency and severity so that he had fallen and injured himself on several occasions. Magnetic resonance imaging  
25 of his abdominal aorta, iliac arteries and carotid arteries confirmed up to 80% occlusion of the lumens of these vessels by atherosclerosis plaques. Doppler ultrasound studies of both lower extremities showed markedly diminished arterial blood flow bilaterally.

30 A percutaneous central venous catheter was inserted into the superior vena cava via the right subclavian vein and initially an intravenous solution having the amino acid composition as set forth in Column B, Table III, above, was infused continuously. The patient initially  
35 received 1.35 grams of amino acids per kilogram body weight or a ration of 95 grams of amino acids as this

formulation. Simultaneously he received 35 calories per kilogram body weight as dextrose together with his daily requirements of vitamins, minerals and trace elements using standard intravenous additives. Baseline metabolic studies were obtained serially throughout the six month treatment and clinical study period. The patient was asked not to ingest any foodstuffs other than water throughout the study.

During the course of antiatherosclerosis infusion therapy and study in the patient, the initial solution formulation was modified on several occasions in response to the plasma cholesterol levels as illustrated in Fig. 1.

As can be seen in Fig. 1, the plasma cholesterol concentration dropped from the initial 508 mg/dL to 450 mg/dL within two days. At point 1, the total daily calories were reduced in the mixture from 2500 (35 cal/kg) to 2100 (30 cal/kg) because the relative inactivity of the patient did not merit the originally calculated caloric requirements. By the eighth day of therapy, the plasma cholesterol level had dropped further to 370 mg/dL, but rose to 393 mg/dL on the ninth day. At point 2, the daily dosages of the branched chain amino acids -- leucine, isoleucine and valine -- were increased by two grams. At this point, the following amino acids were present in the following approximate weight percentages based upon the total weight of the amino acids in the mixtures: isoleucine, 7.9%; leucine, 8.9%; lysine, 5.9%; methionine, 5.0%; phenylalanine, 5.9%; threonine, 3.0%; tryptophane, 2.0%; valine, 7.9%; alanine, 14.9%; arginine, 9.9%; histidine, 3.0%; proline, 7.9%; serine, 5.9%; tyrosine, 0.4%; glycine, 5.9%; glutamic acid, 3.0%; aspartic acid, 2.0%; and cysteine, 0.6%. The amino acid dosage was increased from 1.35 to 1.45 grams per kilogram body weight per day for a daily total ration of 101.5 grams of amino acids as this formulation.

Within ten days of starting the therapy, the plasma

cholesterol level had dropped dramatically to 200 mg/dL, representing a 57% reduction from the starting level of 508 mg/dL. At points 3, 4 and 5, minor changes in concentrations of various amino acid components and dextrose calories were made in response to biochemical determinations made on serum and urine specimens. More specifically, at point 3, the phenylalanine was increased by one gram and the glycine dose was decreased by one gram in the daily amino acid ration. At point 4, the daily dextrose ration was increased to provide 35 cal/kg because the patient had increased his activity and began to lose weight. At point 5, the alanine dose was decreased by three grams while the glutamic acid and aspartic acid dosages were each increased by 1.5 grams in the daily amino acid ration.

At point 6, a dramatic rise in the plasma cholesterol level from 260 to 370 mg/dL occurred following the intravenous infusion of a single 500 ml dose of 10% soybean oil emulsion (sold under the trademark Intralipid®). Points 7 and 8 represent reductions in total calories administered as dextrose to 34 cal/kg and 33 cal/kg, respectively, the plasma cholesterol level remained significantly elevated above its pre-fat infusion nadir for at least four weeks after the infusion of the fat emulsion. By that time it had dropped back to 300 mg/dL, and at point 9, a single 500 ml dose of 20% soybean oil emulsion was given intravenously (Intralipid®) with a rise in the serum plasma cholesterol level to 345 mg/dL, confirming the deleterious effect on the plasma cholesterol level of infusing even essential fatty acids as soybean oil emulsions. At point 10, the daily dextrose calories were reduced to 30 cal/kg, and the daily dosages of proline and serine were each decreased by two grams. Because the patient noted a loss of energy and weight, the glucose ration was restored to 35 cal/kg at point 11. At point 12, the arginine concentration was nearly doubled in

**SUBSTITUTE SHEET**

the solution while the histidine was decreased. A significant drop in plasma cholesterol occurred from 306 mg/dL to 245 mg/dL. The amino acid mixture composition at this point is set forth in Table IV below. The amino acid dosage at this point was increased from 1.45 to 1.5 grams per kilogram body weight per day for a daily total ration of 103.5 grams of amino acids.

TABLE IV

Amino Acid			Amino Acid		
	Weight %	Mol %		Weight %	Mol %
10	Isoleucine	7.7	7.8	Alanine	11.6
	Leucine	8.7	8.6	Histidine	2.4
	Lysine	5.8	4.2	Proline	5.8
	Methionine	4.8	4.3	Serine	3.9
	Phenylalanine	6.8	5.3	Tyrosine	0.4
15	Threonine	2.9	3.2	Glycine	4.8
	Tryptophan	1.9	1.3	Glutamic Acid	4.4
	Valine	7.7	8.6	Aspartic Acid	3.4
	Arginine	16.4	10.2	Cysteine	0.6

During the next week, coronary angiography, magnetic resonance imaging of his aorta, carotid arteries and iliac arteries and doppler ultrasound studies of both lower extremities were repeated. The treatment/study period was then terminated and the patient resumed oral feeding with a restriction of dietary cholesterol to 100 mg daily.

During the six months of treatment, the patient had no angina pectoris or fainting spells; three of the previously four absent extremity pulses could now be palpated; the four previously palpable extremity pulses increased in strength by 50 to 100%; the blood flow to his legs steadily increased up to 250-300% as demonstrated by resting doppler ultrasound studies, and he was able to walk up to 3-4 miles per day at four miles per hour without cramping or claudication in his legs.

At the end of the six month treatment period,

magnetic resonance imaging demonstrated up to a 40-50% decrease in atherosclerosis plaque in the abdominal aorta, common iliac arteries and carotid arteries. Repeat coronary angiography demonstrated widely patent left anterior descending and circumflex coronary arteries, with multiple collateral arteries to the right coronary artery also widely patent except at the point of previous complete occlusion at its origin.

In addition to these dramatic demonstrations of atherosclerosis plaque regression and increased arterial blood flow through multiple previously compromised arteries, further evidence of improved bodily functions was manifested by the patient's ability to play 18 holes of golf while scoring in the 70's, and to gain employment as a carpenter with a housing construction firm. He has remained asymptomatic and active physically for more than 15 months since his therapy was initiated. Continued periodic observation and study occurred to document successful achievement of regression of atherosclerosis and improvement of arterial blood flow and bodily functions, as clearly demonstrated in this patient, are unprecedented with any form of medical or dietary management.

The final solution formulation which evolved during the course of the six month study period in this patient was subsequently infused into an additional ten rabbits as part of a supplementary group of forty rabbits studied in an otherwise identical manner as described above. The regression of atherosclerosis documented in this supplementary group of 10 rabbits was the most effective, consistent and complete of any of the animals studied and ranged from 98% to 99% disappearance of atherosclerotic disease.

### EXAMPLE 3

Additional corroborative evidence of the effectiveness of the method and composition for treating

atherosclerosis was obtained in 30 volunteer human subjects who had been receiving total parenteral nutrition via central venous feeding catheters for two months to eight years. Reductions of plasma cholesterol levels by 40-60% below their usual cholesterol levels regardless of the magnitude of the absolute values were achieved in all of the subjects within one week of changing the aqueous solution infusate to the amino acid compositions as set forth in either Table III or Table IV. These findings are highly significant not only because of the order of magnitude of the reductions in plasma cholesterol levels documented in these subjects, but also because the positive response rate was 100%. All of these patients had been receiving long-term intravenous infusions of conventional TPN substrates containing mixtures of amino acids, without any significant reduction in plasma cholesterol levels. The infusate composition of Table IV caused dramatic reduction.

A striking example of the effectiveness of the solution described in Table IV in reducing plasma cholesterol levels in one patient occurred with the reduction of an already low baseline plasma cholesterol concentration of 83 mg/dL to 50 mg/dL within one week, representing a 40% reduction utilizing an aqueous solution having an amino acid composition as set forth in Table IV.

These data suggest that the mechanism of action of this invention is probably an active biochemical process rather than a result of severe restriction of dietary cholesterol, cholesterol precursors and other lipids, and demonstrate the effectiveness of the present invention.

The compositions and methods of the present invention, as previously described and as illustrated in the examples, provide a unique, potent and effective modality for the treatment of atherosclerosis. The recently completed National Institute of Health sponsored Lipid Research Clinic-Coronary Primary Prevent Trial was

the first study in human beings to establish conclusively that lowering blood cholesterol levels reduces heart attacks and heart attack deaths. However, despite intensive dietary control and administration of

5 pharmacologic plasma cholesterol reducing agents, the average plasma cholesterol level during the ten year study period was reduced by only 8.6% with no higher than a 19% reduction in the best responding patients. However, the incidence of myocardial infarctions in this study group

10 was reduced by up to 19% when compared with the general population. The incidence of myocardial infarctions can be even more significantly reduced in association with the 40-60% reductions in plasma cholesterol levels which have been demonstrated with the use of this invention.

15 It should be noted that many modifications and variations besides the embodiments specifically mentioned may be made in the aforescribed compositions and methods without departing substantially from the concept of the present invention. Accordingly, it should be clearly

20 understood that the form of the invention described and illustrated herein is exemplary only and is not intended as a limitation upon the scope thereof.

CLAIMS

1. An antiatherosclerotic agent for lowering plasma cholesterol levels and reversing arterial plaque deposition and degenerative changes associated with atherosclerosis, consisting essentially of a mixture of biologically active amino acids, said mixture comprising:

- from about 3% to about 10% isoleucine
- from about 3% to about 10% leucine
- from about 2.5% to about 7.5% lysine
- from about 2.5% to about 7.5% methionine
- from about 3% to about 10% phenylalanine
- from about 1% to about 4% threonine
- from about 1% to about 3% tryptophan
- from about 3% to about 10% valine
- from about 2% to about 20% alanine
- from about 7% to about 20% arginine
- from about 1% to about 4% histidine
- from about 0% to about 10% proline
- from about 0% to about 8% serine
- from about 0% to about 1% tyrosine
- from about 0% to about 10% glycine
- from about 0% to about 6% glutamic acid
- from about 0% to about 6% aspartic acid
- from about 0% to about 1% cysteine

by weight based upon the total weight of said biologically active amino acids in said mixture.

2. An antiatherosclerotic agent of claim 1, wherein said mixture further comprises:

- from about 4% to about 10% isoleucine
- from about 5% to about 10% leucine
- from about 4.5% to about 6.5% lysine
- from about 3.5% to about 5.5% methionine
- from about 4.5% to about 7.5% phenylalanine
- from about 2% to about 3.5% threonine



from about 1% to about 2.5% tryptophan  
from about 4% to about 9% valine  
from about 7% to about 16% alanine  
from about 9% to about 18% arginine  
from about 1.5% to about 3.5% histidine  
from about 4.5% to about 8.5% proline  
from about 2.5% to about 6.5% serine  
from about 0% to about 1% tyrosine  
from about 3% to about 8% glycine  
from about 3.5% to about 5.5% glutamic acid  
from about 2% to about 4% aspartic acid  
from about 0% to about 1% cysteine

by weight based upon the total weight of said biologically active amino acids in said mixture.

3. The antiatherosclerotic agent of claim 1, wherein arginine is present within said mixture in the greatest weight percentage based upon the total weight of said biologically active amino acids in said mixture.

4. The antiatherosclerotic agent of claim 1, wherein said biologically active amino acids comprise their levorotatory form.

5. The antiatherosclerotic agent of claim 1, wherein said biologically active amino acids comprise their crystalline form.

6. A composition useful in the treatment of atherosclerosis comprising an active antiatherosclerotic agent consisting essentially of a mixture of biologically active amino acids including at least isoleucine, leucine, valine and arginine present within said composition in an effective amount whereby parenteral administration of said composition in the form of an aqueous solution for an effective period of time results in the substantial lowering of plasma cholesterol and the substantial reversal of arterial plaque deposition and degenerative changes associated with atherosclerosis and whereby arginine is present within said mixture in the greatest

weight percentage based upon the total weight of said biologically active amino acids in said mixture.

7. The composition of claim 6, wherein said mixture further comprises lysine, methionine, phenylalanine, threonine, tryptophan and histidine.

8. The composition of claim 7, wherein said mixture further comprises alanine, proline, serine, tyrosine, glycine, glutamic acid, aspartic acid and cysteine.

9. The composition of claim 6, wherein said biologically active amino acids comprise their levorotatory form.

10. The composition of claim 6, wherein said biologically active amino acids comprise their crystalline form.

11. The composition of claim 6, wherein said mixture further comprises the following mixture of amino acids:

- from about 3.5% to about 10% isoleucine
- from about 3% to about 10% leucine
- from about 2.5% to about 7.5% lysine
- from about 2.5% to about 7.5% methionine
- from about 3% to about 10% phenylalanine
- from about 1% to about 4% threonine
- from about 1% to about 3% tryptophan
- from about 3% to about 10% valine
- from about 2% to about 20% alanine
- from about 7% to about 20% arginine
- from about 1% to about 4% histidine
- from about 0% to about 10% proline
- from about 0% to about 8% serine
- from about 0% to about 1% tyrosine
- from about 0% to about 10% glycine
- from about 0% to about 6% glutamic acid
- from about 0% to about 6% aspartic acid
- from about 0% to about 1% cysteine

by weight based upon the total weight of said biologically

active amino acids in said mixture.

12. The composition of claim 11, wherein said mixture further comprises:

- from about 4% to about 10% isoleucine
- from about 5% to about 10% leucine
- from about 4.5% to about 6.5% lysine
- from about 3.5% to about 5.5% methionine
- from about 4.5% to about 7.5% phenylalanine
- from about 2% to about 3.5% threonine
- from about 1% to about 2.5% tryptophan
- from about 4% to about 9% valine
- from about 7% to about 16% alanine
- from about 9% to about 18% arginine
- from about 1.5% to about 3.5% histidine
- from about 4.5% to about 8.5% proline
- from about 2.5% to about 6.5% serine
- from about 0% to about 1% tyrosine
- from about 3% to about 8% glycine
- from about 3.5% to about 5.5% glutamic acid
- from about 2% to about 4% aspartic acid
- from about 0% to about 1% cysteine

by weight based upon the total weight of said biologically active amino acids within said mixture.

13. The composition of claim 6, further comprising a nutrient supplement.

14. An aqueous solution for use in the treatment of atherosclerosis, a disease characterized by the deposition of fatty substances in and fibrosis of the inner layer of an artery resulting in plaque deposition on and degenerative changes in an arterial wall, comprising:

- an aqueous base; and

- an additive solute comprising an active antiatherosclerotic agent consisting essentially of a mixture of biologically active amino acids comprising isoleucine, leucine, valine and arginine, said additive solute being present within said solution in an effective

amount whereby parenteral administration of said solution for an effective period of time results in the substantial lowering of plasma cholesterol and the substantial reversal of arterial plaque deposition and degenerative changes associated with atherosclerosis.

15. The aqueous solution of claim 14, wherein said mixture further comprises lysine, methionine, phenylalanine, threonine, tryptophan and histidine.

16. The aqueous solution of claim 15, wherein said mixture further comprises alanine, proline, serine, tyrosine, glycine, glutamic acid, aspartic acid and cysteine.

17. The aqueous solution of claim 14, wherein arginine is present within said mixture in the greatest weight percentage based upon the total weight of said biologically active amino acids in said mixture.

18. The aqueous solution of claim 14, wherein said biologically active amino acids comprise their levorotatory form.

19. The aqueous solution of claim 14, wherein said biologically active amino acids comprise their crystalline form.

20. The aqueous solution of claim 14, wherein said mixture further comprises:

- from about 3% to about 10% isoleucine
- from about 3% to about 10% leucine
- from about 2.5% to about 7.5% lysine
- from about 2.5% to about 7.5% methionine
- from about 3% to about 10% phenylalanine
- from about 1% to about 4% threonine
- from about 1% to about 3% tryptophan
- from about 3% to about 10% valine
- from about 2% to about 20% alanine
- from about 7% to about 20% arginine
- from about 1% to about 4% histidine
- from about 0% to about 10% proline

from about 0% to about 8% serine  
from about 0% to about 1% tyrosine  
from about 0% to about 10% glycine  
from about 0% to about 6% glutamic acid  
from about 0% to about 6% aspartic acid  
from about 0% to about 0% cysteine

by weight based upon the total weight of said biologically active amino acids in said mixture.

21. The aqueous solution of claim 20, wherein said mixture further comprises:

from about 4% to about 10% isoleucine  
from about 5% to about 10% leucine  
from about 4.5% to about 6.5% lysine  
from about 3.5% to about 5.5% methionine  
from about 4.5% to about 7.5% phenylalanine  
from about 2% to about 3.5% threonine  
from about 1% to about 2.5% tryptophan  
from about 4% to about 9% valine  
from about 7% to about 16% alanine  
from about 9% to about 18% arginine  
from about 1.5% to about 3.5% histidine  
from about 4.5% to about 8.5% proline  
from about 2.5% to about 6.5% serine  
from about 0% to about 1% tyrosine  
from about 3% to about 8% glycine  
from about 3.5% to about 5.5% glutamic acid  
from about 2% to about 4% aspartic acid  
from about 0% to about 1% cysteine

by weight based upon the total weight of said biologically active amino acids within said mixture.

22. The aqueous solution of claim 14, wherein said additive solute further comprises a nutrient supplement.

23. The aqueous solution of claim 14, wherein said solvent comprises a sterile, ion free water base.

24. The aqueous solution of claim 14, wherein said additive solute is added to said aqueous base in amounts

to produce a concentration of at least about 4 grams of said biologically active amino acids per 100 milliliters of solution.

25. The aqueous solution of claim 24, wherein said additive solute is added to said aqueous base in amounts to produce a concentration of from about 7.5 to about 12 grams of said biologically active amino acids per 100 milliliters of solution.

26. The aqueous solution of claim 25, wherein said additive solute is added to said aqueous base in amounts to produce a concentration of having from about 9 to about 11 grams of said biologically active amino acids per 100 milliliters of solution.

27. A method of treating atherosclerosis, a disease characterized by the deposition of fatty substances in and fibrosis of the inner layer of an artery resulting in plaque deposition on and degenerative changes in an arterial wall, comprising parenterally administering for an effective period of time an effective dose of an aqueous solution comprising an antiatherosclerotic agent to substantially lower plasma cholesterol levels and substantially reverse said plaque deposition and said degenerative changes, wherein said antiatherosclerotic agent comprises a mixture of biologically active amino acids.

28. The method of claim 27, wherein said mixture comprises at least arginine, isoleucine, leucine and valine.

29. The method of claim 28, wherein said mixture further comprises lysine, methionine, phenylalanine, threonine, tryptophan and histidine.

30. The method of claim 29, wherein said mixture further comprises alanine, proline, serine, tyrosine, glycine, glutamic acid, aspartic acid and cysteine.

31. The method of claim 27, wherein arginine is present within said mixture in the greatest weight

percentage based upon the total weight of said biologically active amino acids in said mixture.

32. The method of claim 27, wherein said biologically active amino acids comprise their levorotatory form.

33. The method of claim 27, wherein said biologically active amino acids comprise their crystalline form.

34. The method of claim 27, wherein said mixture further comprises:

- from about 3% to about 10% isoleucine
- from about 3% to about 10% leucine
- from about 2.5% to about 7.5% lysine
- from about 2.5% to about 7.5% methionine
- from about 3% to about 10% phenylalanine
- from about 1% to about 4% threonine
- from about 1% to about 3% tryptophan
- from about 3% to about 10% valine
- from about 2% to about 20% alanine
- from about 7% to about 20% arginine
- from about 1% to about 4% histidine
- from about 0% to about 10% proline
- from about 0% to about 8% serine
- from about 0% to about 1% tyrosine
- from about 0% to about 10% glycine
- from about 0% to about 6% glutamic acid
- from about 0% to about 6% aspartic acid
- from about 0% to about 1% cysteine

by weight based upon the total weight of said biologically active amino acids in said mixture.

35. The method of claim 34, wherein said mixture further comprises:

- from about 4% to about 10% isoleucine
- from about 5% to about 10% leucine
- from about 4.5% to about 6.5% lysine
- from about 3.5% to about 5.5% methionine

from about 4.5% to about 7.5% phenylalanine  
from about 2% to about 3.5% threonine  
from about 1% to about 2.5% tryptophan  
from about 4% to about 9% valine  
from about 7% to about 16% alanine  
from about 9% to about 18% arginine  
from about 1.5% to about 3.5% histidine  
from about 4.5% to about 8.5% proline  
from about 2.5% to about 6.5% serine  
from about 0% to about 1% tyrosine  
from about 3% to about 8% glycine  
from about 3.5% to about 5.5% glutamic acid  
from about 2% to about 4% aspartic acid  
from about 0% to about 1% cysteine

by weight based upon the total weight of said biologically active amino acids in said mixture.

36. The method of claim 27, wherein said aqueous solution further comprises an aqueous base.

37. The method of claim 36, wherein said aqueous base comprises a sterile, ion free water base.

38. The method of claim 36, wherein said aqueous solution further comprises a caloric supplement.

39. The method of claim 27, wherein said antiatherosclerotic agent is added to said aqueous base in amounts to produce a concentration of at least about 4 grams of said biologically active amino acids per 100 milliliters of solution.

40. The method of claim 39, wherein said antiatherosclerotic agent is added to said aqueous base in amounts to produce a concentration of from about 7.5 to about 12 grams of said biologically active amino acids per 100 milliliters of solution.

41. The method of claim 40, wherein said antiatherosclerotic agent is added to said aqueous base in amounts to produce a concentration of from about 9 to about 11 grams of said biologically active amino acids per



100 milliliters of solution.

42. The method of claim 27, wherein said aqueous solution is parenterally administered in an effective dose comprising from about 0.25 to about 3 total grams of biologically active amino acids per kg of body weight per day.

43. The method of claim 42, wherein said aqueous solution is parenterally administered in an effective dose comprising from about 1 to about 2 total grams of biologically active amino acids per kg of body weight per day.




FIG. 1

# INTERNATIONAL SEARCH REPORT

International Application No PCT/US 87/02279

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>4</sup> :     A 61 K 37/18; A 61 K 31/195																							
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; margin-top: 10px;">Minimum Documentation Searched <sup>7</sup></div> <table style="width: 100%; border: none;"> <tr> <td style="width: 25%; border: none;">Classification System</td> <td style="border: none;">Classification Symbols</td> </tr> <tr> <td style="border: none; vertical-align: top;">IPC<sup>4</sup></td> <td style="border: none; vertical-align: top;">A 61 K</td> </tr> </table> <div style="text-align: center; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup></div>			Classification System	Classification Symbols	IPC <sup>4</sup>	A 61 K																	
Classification System	Classification Symbols																						
IPC <sup>4</sup>	A 61 K																						
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category <sup>9</sup></th> <th style="width: 70%;">Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup></th> <th style="width: 20%;">Relevant to Claim No. <sup>13</sup></th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top;">X,Y</td> <td>DE, A, 3228127 (BASF AG) 2 February 1984 see pages 8-9, examples 6,7; page 1, claim</td> <td style="text-align: center; vertical-align: top;">1-26</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td style="text-align: center;">--</td> <td></td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td>Chemical Abstracts, volume 99, no. 3, 18 July 1983, (Columbus, Ohio, US), D. Kritchevsky et al.: "Dietary proteins and atherosclerosis", see page 518, abstract 21269d, &amp; Soy Protein Prev. Atheroscler., Proc. Int. Symp., 4th 1981 (Pub. 1982), 1-11</td> <td style="text-align: center; vertical-align: top;">1-26</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td style="text-align: center;">--</td> <td></td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td>Chemical Abstracts, volume 97, no. 7, 16 August 1982, (Columbus, Ohio, US), M.B. Katan et al.: "Reduction of casein-induced hypercholesterolemia and atherosclerosis in rabbits and rats by dietary glycine, arginine and alanine", see page 532, abstract 54482e, &amp; Atherosclerosis (Shannon, Irel.) 1982, 43(2-3), 381-91</td> <td style="text-align: center; vertical-align: top;">1-26</td> </tr> <tr> <td></td> <td style="text-align: center;">--</td> <td></td> </tr> </tbody> </table>			Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	X,Y	DE, A, 3228127 (BASF AG) 2 February 1984 see pages 8-9, examples 6,7; page 1, claim	1-26	Y	--		Y	Chemical Abstracts, volume 99, no. 3, 18 July 1983, (Columbus, Ohio, US), D. Kritchevsky et al.: "Dietary proteins and atherosclerosis", see page 518, abstract 21269d, & Soy Protein Prev. Atheroscler., Proc. Int. Symp., 4th 1981 (Pub. 1982), 1-11	1-26	Y	--		Y	Chemical Abstracts, volume 97, no. 7, 16 August 1982, (Columbus, Ohio, US), M.B. Katan et al.: "Reduction of casein-induced hypercholesterolemia and atherosclerosis in rabbits and rats by dietary glycine, arginine and alanine", see page 532, abstract 54482e, & Atherosclerosis (Shannon, Irel.) 1982, 43(2-3), 381-91	1-26		--	
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>																					
X,Y	DE, A, 3228127 (BASF AG) 2 February 1984 see pages 8-9, examples 6,7; page 1, claim	1-26																					
Y	--																						
Y	Chemical Abstracts, volume 99, no. 3, 18 July 1983, (Columbus, Ohio, US), D. Kritchevsky et al.: "Dietary proteins and atherosclerosis", see page 518, abstract 21269d, & Soy Protein Prev. Atheroscler., Proc. Int. Symp., 4th 1981 (Pub. 1982), 1-11	1-26																					
Y	--																						
Y	Chemical Abstracts, volume 97, no. 7, 16 August 1982, (Columbus, Ohio, US), M.B. Katan et al.: "Reduction of casein-induced hypercholesterolemia and atherosclerosis in rabbits and rats by dietary glycine, arginine and alanine", see page 532, abstract 54482e, & Atherosclerosis (Shannon, Irel.) 1982, 43(2-3), 381-91	1-26																					
	--																						
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as-specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>																							
<b>IV. CERTIFICATION</b> <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;">           Date of the Actual Completion of the International Search             18th January 1988         </td> <td style="width: 50%; border: none; vertical-align: top;">           Date of Mailing of this International Search Report  <div style="text-align: right; font-weight: bold;">15 FEB 1988</div> </td> </tr> <tr> <td style="border: none; vertical-align: top;">           International Searching Authority             EUROPEAN PATENT OFFICE         </td> <td style="border: none; vertical-align: top;">           Signature of Authorized Officer  <div style="text-align: right; font-weight: bold;">P.C.G. VAN DER PUTTEN</div> </td> </tr> </table>			Date of the Actual Completion of the International Search  18th January 1988	Date of Mailing of this International Search Report <div style="text-align: right; font-weight: bold;">15 FEB 1988</div>	International Searching Authority  EUROPEAN PATENT OFFICE	Signature of Authorized Officer <div style="text-align: right; font-weight: bold;">P.C.G. VAN DER PUTTEN</div>																	
Date of the Actual Completion of the International Search  18th January 1988	Date of Mailing of this International Search Report <div style="text-align: right; font-weight: bold;">15 FEB 1988</div>																						
International Searching Authority  EUROPEAN PATENT OFFICE	Signature of Authorized Officer <div style="text-align: right; font-weight: bold;">P.C.G. VAN DER PUTTEN</div>																						

# BEST AVAILABLE COPY

International Application No. PCT/US 87/02279

-2-

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

A	US, A, 2965542 (ALBERT CASTAIGNE) 20 December 1960 see column 7, lines 62-68; claim 1	1-26
A	US, A, 3574857 (WILLIAM H. CEVALLOS) 13 April 1971 see column 4, lines 42-60; claims 1-5	1-26

### V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers XX because they relate to subject matter not required to be searched by this Authority, namely:

XX Claims 27-43

Please refer to PCT Rule 39.1(iv)

Methods for treatment of the human or animal body by means of surgery or therapy, as well as diagnostic methods.

2. ☐ Claim numbers..... because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers..... because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(e).

### VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This international Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the international Searching Authority did not invite payment of any additional fee.

Remark on Protest

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

**US 8702279**

**SA 18805**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 08/02/88. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE-A- 3228127	02-02-84	None	
US-A- 2965542		None	
US-A- 3574857	13-04-71	None	